HOME >> BIOLOGY >> NEWS
JCI Table of contents August 1, 2005

p?id=23076

ACCOMPANYING COMMENTARY:

TITLE: Weaving beta Klotho into bile acid metabolism

AUTHOR CONTACT:
Steven Kliewer
University of Texas Southwestern Medical Center, Dallas, TX USA
Phone: 214-645-6304; Fax: 214-645-6305; E-mail: steven.kliewer@utsouthwestern.edu

View the PDF of this article at: https://www.the-jci.org/article.php?id=26046

PHYSIOLOGY
Insulin spares intensive care patients from organ failure and death

It was previously shown, in a large, randomized, controlled trial that controlling blood glucose with insulin reduces the risk of organ failure and death of patients in intensive care. But the underlying mechanisms explaining these clinical benefits remained incompletely understood.

In a new study appearing on August 1 in The Journal of Clinical Investigation, the same group, Greet Van den Berghe and colleagues from Katholieke Universitiet Leuven, show that there is disturbed microcirculation in these patients that is due to endothelial dysfunction which causes inadequate oxygen supply to the cellular systems. The endothelium controls vascular flow and trafficking of important biological molecules. The endothelium of patients with prolonged critical illness is protected by strict blood glucose control with insulin and this may play a major role in the prevention of organ failure and death with this treatment.

This data may open perspectives for novel treatments and for progress in intensive care medicine. In an accompanying commentary, Dandona, et al write, "the results suggest a new paradigm in which glucose and insulin are related not only through their metabolic actions but also through their opposite effects on inflammatory mechanisms."

TITLE: Intensive insulin therapy protects the
'"/>

Contact: Stacie Bloom
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
1-Aug-2005


Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology news :

1. JCI Table of Contents -- July 2, 2007
2. JCI Table of Contents: July 13, 3006
3. JCI Table of Contents, June 15 2006
4. JCI Table of Contents, April 13, 2006
5. JCI Table of Contents, March 1, 2005
6. JCI table of contents: Aug. 9, 2007
7. JCI table of contents: August 1, 2007
8. JCI table of contents -- July 26, 2007
9. JCI table of contents: July 19, 2007
10. JCI table of contents: July 12, 2007
11. JCI table of contents: June 21, 2007

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/20/2017)... Germany , March 20, 2017 At this ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG ... is this year,s CeBIT partner country. At the largest German ... biometrics in use: fingerprint, face and iris recognition as well as DERMALOG´s ... ...
(Date:3/13/2017)... Germany , March 13, 2017 Future of security: ... ... DERMALOGs Face Matching enables to match face ... forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
(Date:3/23/2017)... ALBANY, New York , March 23, 2017 ... animal blood plasma products and derivatives market is fragmented due to the ... large players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, ... clear leader, these three companies, collectively, held more than 76% of ... ...
Breaking Biology Technology:
Cached News: